UNDERSTANDING WHAT MATTERS MOST

An Overview for Investors
June 2025

SecuraBio

SAFE-HARBOR STATEMENT

This presentation has been prepared by SecuraBio Holdings, Inc. ("we," "us," "our," "SecuraBio" or the "Company") and includes certain “forward looking statements”, including statements regarding the timing of clinical development milestones for our clinical assets, revenue of our commercial products, as well as statements relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, and the prospects for commercializing or selling any product or drug candidates. In addition, when or if used in this presentation, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience. The statements made herein speak only as of the date stated herein, and any forward-looking statements contained herein are based on assumptions that the Company believes to be reasonable as of this date. The Company undertakes no obligation to update these statements as result of new information or future events.

CORPORATE HIGHLIGHTS

1

Commercial-stage pharmaceutical company
- Deep expertise in oncology and hematology

2

Optimizing COPIKTRA® (duvelisib) growth
- +22% CAGR since launch; $40million in annual net sales
- Phase 3 label expansion study underway

3

Building a portfolio of assets developed internally, through acquisition, or in-licensing
- Actively assessing assets in hematology, oncology and other specialty markets

EXPERIENCED MANAGEMENT TEAM

Chip Romp
President & CEO

- 25+ years pharmaceutical industry leadership experience
- Extensive background in oncology/immunology
- Proven ability to build successful global companies

Will Brown
Chief Financial Officer

- 20+ years finance experience
- CFO roles in multiple life science companies, public and private
- Extensive debt and equity financing experience

David Sidransky, MD
Medical Advisor

- 30+ years life science experience
- Extensive clinical experience in medical oncology
- Leadership roles in medical affairs and clinical development for both solid tumor and heme assets

Greg Wessels
Commercial Strategy and Operations

- 20+ years life science experience
- Senior level marketing roles in oncology
- Developed and executed marketing strategies at global, regional and local levels

Dr. Juan Estruch
Head of Corporate Development

- 25+ years life science experience and co-founder of Secura
- Extensive experience in product assessment, corporate strategy, and corporate development
- Proven track record of identifying assets for repositioning or relaunch

MANAGEMENT EXPERIENCED IN CREATING VALUE

History of Successful Launches

Have played an instrumental part in commercializing some of the industry's largest products

OUR PIPELINE

Duvelisib

See our website www.securabio.com/clinical-development

Copiktra® (duvelisib) 15mg | 25mg capsules

A Novel PI3Ki oral treatment for difficult to treat or relapsed / refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) patients that have been exposed to BTK and BCL2 inhibitors

Read the Important Safety Information and patient Medication Guide in the full Prescribing Information that includes information about serious side effects with COPIKTRA®.

CUSTOMER FACING TEAM WITH A NATIONAL FOOTPRINT

We are pursuing assets with a concentrated prescriber base to leverage our strengths and allow us to unlock value:

Full in-house Commercial capabilities covering entire U.S.

★ COPIKTRA Key Account

Focused on NCCN/NCI Treatment Centers

All Major Regional Cancer Treatment Groups Covered

Full Commercial and Medical Team Functions

CURRENT TOTAL ADDRESSABLE MARKET

Patient Incidence Rate



Current Market Share



- ~11% share of the U.S. r/r PTCL Market
- Significant opportunity to increase share

Significant Opportunity Within the R/R Patient Population

A CLINICAL STRATEGY FOR CONTINUED GROWTH

LEVERAGING PI3K'S ROLE IN HEMATOLOGIC MALIGNANCIES



Personalized Medicine in Oncology: Duvelisib. Available at: https://www.personalizedmedonc.com/supplements/mechanism-of-action-magnifier---2016-desk-reference/2283:duvelisib-ipi-145-a-dual-inhibitor-of-phosphoinositide-3-kinase-pi3k-delta-and-gamma

Dysregulation and hyperactivity of PI3K signaling can result in malignancy;

PI3K plays a critical role in regulating the growth and survival of some hematological cancers[1,2]

1. Lampson BL, et al. Hematol Oncol Clin North Am. 2021;35(4):807-826. 2. Kashani B, et al. Expert Review of Anticancer Therapy. 2024:1-20. 3. Schmid MC, et al. Cancer Cell. 2011;19(6):715-27. 4. Yang J, et al. Mol Cancer. 2019;18(1):26; 5. Schmid VK, et al. Front Oncol. 2024;14:1339620.

COMPELLING CLINICAL DATA SET IN PERIPHERAL T-CELL LYMPHOMAS













VERY ACTIVE AGENT WITH HIGH COMPLETE RESPONSE RATE



1. Zinzani PL, et al. Poster presented at the European Hematology Association Annual Meeting. Vienna, Austria, June 9-17, 2022

PRIMO PHASE 2 STUDY DEMONSTRATED STRONG SURVIVAL BENEFIT



AITL = Angioimmunoblastic T cell lymphoma; ALCL = Anaplastic large cell lymphoma, EP = Expansion phase, IRC = Independent review committee, OS = Overall survival, PFS = Progression free survival, PTCL-NOS = Peripheral T cell lymphoma not elsewhere specified

DUVELISIB IN AITL

Progression-free Survival (by IRC)

9 months

Overall Survival

18 months

DUVELISIB CONTINUES TO EXPAND PRESENCE IN NCCN GUIDELINES

December 2021:
Data Presentation at ASH
PRIMO Interim Analysis. N = 78

June 2022:
Data Presentation at EHA
Updated Expansion Phase Analysis, Zinzani et. al.

June 2023:
Data Presentation at EHA
Outcomes by Histology, Mehta-Shah et. al.
.

November 2024:
NCCN Enhanced Recommendation for Use
Combination duvelisib + romidepsin added to guidelines

NCCN

Data

December 2021:
NCCN Designation
NCCN (V1-Jan 2022): Designated duvelisib as Category 2A for all subtypes of r/r PTCL

December 2022:
Data Presentation at ASH
Impact of Prior Treatment, Jacobsen et. al.

December 2023:
NCCN Enhanced Recommendation for Use
NCCN (V4-2024): Upgraded duvelisib from 'other recommended regimens' to 'preferred regimens' for AITL, including Nodal, PTCL, TFH, and FTCL, for both intention to proceed to transplant and no intention to proceed to transplant.

TFH PHENOTYPE IS POTENTIALLY THE LARGEST PTCL SUBTYPE



40-50%
TFH Phenotype

10-20%
PTCL-NOS

30-50%
All Other

Source: clinicaloptions.com

PHASE 3 TERZO™ STUDY:

A multi-centre, open-label, phase 3, randomized controlled trial of duvelisib versus investigator's choice of gemcitabine or bendamustine in patients with relapsed/ refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype (TERZO)

The use of duvelisib in T cell lymphoma is investigational; safety and efficacy of duvelisib have not been established by any regulatory agency globally

TERZO™ STUDY DESIGN

Main eligibility criteria

Patients (≥ 18 years) with pathologically confirmed R/R nodal T-cell lymphoma with TFH phenotype[1]

- Measurable disease[2]
- ECOG performance score ≤2
- No more than ≥1 prior line of therapy
- No prior history of allogeneic SCT
- No prior therapy with PI3K inhibitors
- No CNS involvement or cutaneous only disease
- No prior gemcitabine or bendamustine within 60 days

Randomisation 1:1 (N = 124)

Stratified by AITL score (0-2 vs. 3-4), number of prior therapies, and country



PD, progressive disease
SD, stable disease
PR, partial response;
CR, complete response

Response assessment[2] every 8 weeks

Endpoints

Primary endpoint
Progression Free Survival[1] (PFS): Time from randomization to documented PD, as assessed by the IRC, or death due to any cause

Key Secondary endpoint
Overall Survival (OS): Time from randomization to death due to any cause

Duvelisib: C1 & 2: 75 mg orally twice daily in 28-day cycles; C3+ 25 mg twice daily in 28-day cycles[4]
Gemcitabine: Gemcitabine 1200mg/m2 IV days 1,8,15 of a 28-day cycle (up to 6 cycles)
Bendamustine: 120 mg/m2 administered IV over 30 minutes on days 1 and 2 of a 28-day cycle (up to 6 cycles)

1. Definition by World Health Organization (Swerdlow 2017); 2. Response assessment per Lugano 2014 Criteria (Cheson 2014)
3. Investigator's choice of comparator must be declared prior to randomisation 4. Continue treatment until PD, unacceptable toxicity, or withdrawal

PHASE 3 STUDY MILESTONES

Q4 2024	Initiate Phase 3 study
Q1 2025	First patient in
MID 2026	Interim data read out
2028	Final data

ADDITIONAL STRATEGIC OPPORTUNITIES

BUSINESS DEVELOPMENT STRATEGIC FRAMEWORK

Key Acquisition Criteria:

1. Oncology/Hematology
2. Commercial stage
3. Overlaps our existing footprint
4. Serving critical unmet medical needs
5. Opportunity to increase value

SUMMARY

1 Revenue generating company in oncology

2 Near-term focus on accelerating COPIKTRA growth

3 Long-term focus on strategic acquisitions to build value

4 Management team experienced in identifying & securing assets

UNDERSTANDING WHAT MATTERS MOST

An Overview for Investors
June 2025

SecuraBio